Sam Tetlow's Location
New York, New York, United States, United States
Sam Tetlow's Contact Details
Sam Tetlow work email
- Valid
- Valid
- Valid
- Valid
Sam Tetlow personal email
n/a
About Sam Tetlow
Established Leader with proven track record of growing companies in the life sciences.Specialized experience in working with emerging life science companies in the leading research and clinically-relevant applications (including cGMP/GLP/CLIA) of epigenetics, genomics, diagnostics, tools, device and selected therapeutic development programs. Additional demonstrated experience in research-stage technologies and applications. Experience in successfully leading management teams in high-technology companies protected by IP with high-growth potential.
Sam Tetlow's Current Company Details
Sam Tetlow Work Experience Details
-
Founder And CeoGrant EngineNew York, Ny, Us
-
Founder & CeoGrant Engine Oct 2015 - PresentDurham, North Carolina, UsAt Grant Engine we are entrepreneurs ourselves and know how to build companies. We apply this necessary expertise to securing grants from NIH, DoD and other sources. After developing my last two companies on grant funding from NIH and the DoD, combined with equity, I launched the platform Grant Engine about 4 years ago. With win rates at 2 to 4x better than the national average, a proven team, and a focus on advancing differentiated products that improve standard of care we partner with select companies.
-
President & ChairmanAmalgent Therapeutics Feb 2020 - PresentGreenville, Nc, UsAmalgent is a clinical-stage pain management company that is developing its first oral combination therapeutics for the US market. We understand that severe pain is a global challenge and that existing medications provide patients and their families with inadequate care. Amalgent is developing combination drugs that dramatically reduce the doses required for effective analgesia with lower doses come minimized side effects. -
ChairmanPrimeneuro Mar 2018 - PresentGrowing Neurodiversity. PrimeNeuro is building smart software for early diagnosis, intervention, and management in developmental disabilities, including tools to support parents as they manage the chronic stress of raising a child with developmental delays. While we believe deeply in the need for research and products to support children and adults living with developmental delay, we also respect the needs of care providers as they manage a lifetime of uncertainty.
-
Member Board Of DirectorsRtp Capital Associates Mar 2015 - Present -
Nike Product Tester (Running)Nike Jan 2006 - PresentBeaverton, Or, Us -
Chairman Of The BoardBiofluidica, Inc. Jan 2014 - Nov 2021Led the Board of Directors in setting strategy, providing resources for CEO and Team, and ensure effective corporate governance. Support execution of business strategy as Chief Business Officer. Led fundraising of $1.9 million (Fall, 2015) of successful NIH grants that enabled initial full-time management to join. Recruited company's first CEO (Oct, 2015). Worked jointly with CEO to secure $2 million in equity (May, 2016). BioFluidica is a privately held biotechnology company that has developed a diagnostic platform allowing for disease management and diagnosis through prognosis, all from a simple blood test. The Biofluidica diagnostic platform is able to precisely capture and isolate disease biomarkers, such as Circulating Tumor Cells, CTC's, and has been clinically validated. Our ability to scan blood for the first signs of a disease, finding the rarest biomarkers with unmatched sensitivity, means fulfilling the promise of a true liquid biopsy. We are revolutionizing disease diagnostics by bringing better diagnostics to millions of people. -
Chief Executive OfficerEpicypher - Pioneering The Science Of Epigenetics™ Sep 2013 - Dec 2016Durham, North Carolina, UsEstablish vision and strategy for company. Oversee operational execution, strategic partnership development, fundraising, recruiting, and allocation of capital for leading epigenetics firm. Led company from early revenue through cash flow positive operations. * Lead team of seventeen science and operations personnel. Negotiated key licenses for IP and Facilities between UNC and EpiCypher. * Secured partnership deals between PerkinElmer and EpiCypher to compensate for product development and co-marketing agreement. * Active sales and business development role with customers, partners and suppliers. * Led organization to growing revenues, sustainable engine for non-dilutive funding, and cash-flow positive operations. * Oversee Intellectual Property estate, in conjunction with lead scientists and external IP counsel. -
General ManagerIls Genomics Jun 2012 - Sep 2015Identified, negotiated, and closed asset purchase from Beckman Coulter Genomics into the newly formed ILS Genomics, LLC in June 2012. Once closed, I led the organization from zero revenue at purchase to annual run rate exceeding $2.5 million in the first year.
-
PartnerResearch Triangle Ventures Jan 2001 - Jun 2014Early stage venture capital fund. Board of Director responsibility, fundraising, due diligence, deal sourcing and overall fund management.Gentris (genomics): Board member. Led investment thesis for Series A; lead RTV resource for Series B fundraising. Successfully sold one division, 8/07 and grew remaining business with industry leading growth rates. Recruited current Board of Directors and CEO. While there we established highly attractive cash flow levels with industry leading EBITDA margins. Tranzyme Pharma (Therapeutics): Investment thesis, Fundraising, Observed on BOD. Company raised $75 million and went IPO on April, 2011. Noverant (healthcare software): Developed original business plan, secured industry leading partnerships. Member of BOD. Sold company in private sale in 2006.LVL7 Systems (communications software): Sourced investment opportunity with USVP and The Carlyle Group; led RTV's investment thesis. Successful exit to Broadcom.
-
PartnerResearch Triangle Ventures Sep 2001 - Oct 2008Early stage venture capital fund. Board of Director responsibility, fundraising, due diligence, deal sourcing and overall fund management. Promoted from Associate.
-
Chief Business OfficerIntegrated Laboratory Systems Jan 2011 - Jul 2013Research Triangle Park, Nc, UsMr. Tetlow is responsible for working with the Chairman of the Board and the executive leadership team to set the Company’s overall strategy, and grow the business both organically and strategically. He works closely with the CEO to reinforce the company’s values across the company and expand ILS capabilities in important areas of research and medicine. -
PartnerRespirics Aug 2001 - Mar 2012UsRespirics was purchased by Zhejiang Hisun Pharmaceutical Co Ltd, in January 2012. Respirics was a pulmonary drug delivery and development company. The company offered MD Turbo, a breath-activated accessory device for use with metered-dose inhalers, Nebulizers , Acu-Breathe single, and multi-dose dry powder inhalers. The company serves asthma and COPD patients, and pharmaceutical companies. Role: Investment into respiratory medical device firm. Led due diligence and deal structuring for early stage convertible note, pre Series A. Facilitated fundraising for Series A. $2.5m Facilitated exit to international pharmaceutical company. -
Board MemberImmunologix, Inc. Jan 2010 - Dec 2011Immunologix was purchased by Intrexon (www.dna.com) in Oct, 2011 for a successful exit within 24 months. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis.From its exclusive patent license from the Medical University of South Carolina, Immunologix developed mAbLogix™ platform to deliver a key unmet need in antibody-based therapeutics. Importantly, the mAbLogix™ technology platform enables the unique ability to derive fully human antibodies using a 100% in vitro system – thus avoiding the substantial limitations and time consuming requirements of animal-derived antibodies. -
PartnerTranzyme Pharma Dec 2001 - Apr 2011Investment Board of Director observer. Led due diligence and co-lead for deal structuring for Series A. $26m Currently monitor investment.
-
Chairman Of The Board, DirectorGentris Corporation Aug 2007 - Jan 2011Investment, Sale of Company. Continued monitoring Board of Director. Led due diligence and deal structuring for Series A. Facilitated fundraising for Series B and Series C. $8.1m Successful exit for one of two divisions (8/07). Current Board of Director.
-
Vp Of Business DevelopmentCalvert Research Jan 2010 - Nov 2010Business Development lead for Calvert Research.
-
AuthorDrug & Market Development Oct 2001 - May 2007- Successful Pharmacogenomics Business Models (143 pg Industry Report; 11/03)- Outsourcing Research & Development (173 pg Industry Report; 5/04)- Pharmaceutical Industry Outlook (186 pg Industry Report; 2/05)
-
PartnerSmartpath, Inc Feb 2003 - Nov 2006/04 Investment, Sale of Company. Led due diligence and co-lead for Series A. $10m Company sold to DoubleClick: 3/2004.
-
PartnerLvl7 Systems Software Sep 2001 - Oct 2006/06 Investment, Sale of Company. Sourced deal. Led due diligence and co-lead for deal structuring for Series A. Facilitated fundraising for Series B and Series C. $44m Company sold to Broadcom: 12/2006.
-
Coo, PartnerNoverant, Inc Feb 2002 - Oct 2005/06 Investment, Sale of Company. Took over as Interim COO and Board of Director. Led due diligence and deal structuring for Series A. Led fundraising for Series B. $4m Company sold to GCG, Inc.: 3/2006.
-
PartnerExervio Consulting Software Consulting Apr 2000 - Sep 2001Acquisition Lead member of buyout team. Negotiated Purchase Agreement from Parent company. Facilitated deal structure, team equity split and organized new management team. $10m Concluded purchase agreement. Founding member of management team.
-
Director, StrategyExervio Management Consulting Jan 2000 - Sep 2001Charlotte, Nc, UsFoudner. Managed strategy consulting practice. Responsible for P&L, business development, engagement delivery and pricing.Executed Exervio buy-out from marchFIRST with Exervio CEO & management. Assisted in generating revenue of $1.9 million (40% increase) and profit of $0.4 million (45% increase), in part via TARSAS software solution for major financial services client.Screened venture capital investments for BlueVector fund. Supported start-ups with funding strategy, marketing plans and cash management. -
Founder & DirectorExervio Consulting, Inc Jan 2000 - Jan 2001of Strategy. Managed strategy consulting practice. Responsible for P&L, business development, engagement delivery and pricing.Executed Exervio buy-out from marchFIRST with Exervio CEO & management. Assisted in generating revenue of $1.9 million (40% increase) and profit of $0.4 million (45% increase), in part via TARSAS software solution for major financial services client.Screened venture capital investments for BlueVector fund. Supported start-ups with funding strategy, marketing plans and cash management.
-
Senior Financial AnalystGe Polymerland Jan 1997 - Jan 2000Manager, Finance. Directed 3-year & annual financial plan and quarterly closing process to exceed financial commitments for $1B business. Managed 8 individuals in Mexico and Charlotte.Contributed to the investment thesis, business model and realization of GE Company's first e-Commerce platform: polymerland.com.Led due diligence and acquisition of $31 million firm in Mexico City. Exceeded integration synergy goal of $1 million by 50%.Managed $55 million budget including capital expenditures and business staffing plan. Reduced expenses by 10% and 11% in 1998 and 1999.; Lead role in product line profitability analysis, fixed cost management and foreign exchange hedging.Successful $18m market share shift to GE Plastics product from supplier management, achieving $1.5m income gain.Successful implementation of foreign exchange strategy for $100m revenue.Completed highest GE Six Sigma quality certification.
-
Director Of M&APolimeros Y Quimicos Engineered Plastics Nov 1998 - Dec 1999Acquisition Sourced deal opportunity, negotiated final Purchase Agreement, structured transaction, led due diligence. $31m Concluded purchase, and subsequently managed business with profit & loss responsibility.
-
Manager, FinanceGe Sep 1993 - Dec 1999Boston, Ma, Us1998 – 2000 GE POLYMERLAND Charlotte, NCManager, Finance. Directed 3-year & annual financial plan and quarterly closing process to exceed financial commitments for $1B business. Managed 8 individuals in Mexico and Charlotte.Senior Financial Analyst. Lead role in product line profitability analysis, base cost management and foreign exchange hedging.- Completed highest GE Six Sigma quality certification.1995 – 1998GE CORPORATE AUDIT STAFF Fairfield, CTSenior Associate. Offered Senior Manager position. Conducted operational and financial reviews on global 4-month rotations on behalf of Office of the Chairman. Emphasis on leadership development via strategic reviews and business unit financial verification. 1993 – 1995 GE POWER SYSTEMS Schenectady, NYSales Manager – Technical Leadership Program. Two-year training program on six month rotations in multiple functions and responsibilities. Promoted from proposal sales manager in 1994. -
Senior AssociateGe Jan 1995 - Jan 1997Boston, Ma, UsConducted operational and financial reviews on global 4-month rotations on behalf of Office of the Chairman. Emphasis on leadership development via strategic reviews and business unit financial verification. Conducted M&A due diligence with cross-functional team on Philippine Airlines ($50 million, Manila) and Danje Polymers ($15 million, Warsaw). Achieved cost reduction efforts with GE Aircraft Engines Engineering teams on the GE90 (Boeing 777 engine), meeting $34 million goal. Conducted valuation review for $257m of GE Plastics inventory, resulting in $1.5m adjustment; reviewed $21 million inventory surplus and implemented corrective actions. Introduced cost optimization model for GE Appliances distribution network successfully reducing cost by $1m with negligible service impact.Completed numerous financial audits in GE Capital businesses.
-
Director Of M&ADanje Polymers Engineered Plastics Jun 1997 - Jul 1999Acquisition Negotiated final Purchase Agreement, via structured transaction. Led due diligence. $15m Concluded purchase. Instrumental in integrating the business into GE Polymerland.
-
Director Of M&APhilippine Airlines, Services Airline Sep 1996 - Mar 1998Acquisition Led due diligence. Drove deal negotiation and facilitated consummation of the acquisition. $50m Concluded purchase. Instrumental in integrating the business into GE Engine Services.
-
Sales ManagerGe Power Systems Jan 1993 - Jan 1995Technical Leadership Program. Two-year training program on six month rotations in multiple functions and responsibilities. Promoted from proposal sales manager in 1994. Completed proposals and contributed to deal signing for Akzo Nobel ($350m) & Central Jersey Power & Light ($150m).Managed long-term customer relationships ranging in size from $35m to $750m.
Sam Tetlow Skills
Start Ups
Strategy
Biotechnology
Mergers And Acquisitions
Business Development
Entrepreneurship
Medical Devices
Venture Capital
Cross Functional Team Leadership
Leadership
Executive Management
Life Sciences
Management
Pharmaceutical Industry
Business Planning
Outsourcing
Commercialization
Strategic Planning
Pharmacogenomics
Management Consulting
Budgets
Due Diligence
Sales
Mergers
Drug Development
Valuation
Technology Transfer
R&d
Strategic Partnerships
Lifesciences
Finance
Analysis
Investments
Corporate Development
E Commerce
Marketing
Product Development
Competitive Analysis
Software Development
Sam Tetlow Education Details
-
Unc Kenan-Flagler Business SchoolVenture Capital & Entrepreneurship -
Worcester Polytechnic InstituteAerospace Engineering
Frequently Asked Questions about Sam Tetlow
What company does Sam Tetlow work for?
Sam Tetlow works for Grant Engine
What is Sam Tetlow's role at the current company?
Sam Tetlow's current role is Founder and CEO.
What is Sam Tetlow's email address?
Sam Tetlow's email address is sa****@****ica.com
What schools did Sam Tetlow attend?
Sam Tetlow attended Unc Kenan-Flagler Business School, Worcester Polytechnic Institute.
What are some of Sam Tetlow's interests?
Sam Tetlow has interest in Mobile, Clean Technology, Health Care, Consumer Internet, Enterprise Software.
What skills is Sam Tetlow known for?
Sam Tetlow has skills like Start Ups, Strategy, Biotechnology, Mergers And Acquisitions, Business Development, Entrepreneurship, Medical Devices, Venture Capital, Cross Functional Team Leadership, Leadership, Executive Management, Life Sciences.
Who are Sam Tetlow's colleagues?
Sam Tetlow's colleagues are Dan Mark Garcia, Samia O'bryan, Phd, Catherine (Cally) Burkhart, William Lawrence, Phd, Kristin Caruana Scott, Phd., Randolph Mckinley, El Cameron.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial